First drug safety report
This article was originally published in The Tan Sheet
Executive Summary
FDA posts its first quarterly report of drugs under investigation for potential safety issues based on adverse event reports. The report meets a provision of the Food and Drug Administration Amendments Act and is intended to increase transparent communication. Published Sept. 5, the inaugural report lists 20 drugs and their potential adverse effects that FDA identified between January and March. For example, the list includes duloxetin (Eli Lilly's Cymbalta) for possible urinary retention. While the first report lists only prescription drugs, future reports could include OTC drugs. FDA stresses consumers should not stop taking a drug just because it appears on the list. The agency says its communication is preliminary and an investigation may determine an adverse event is not drug-relatedYou may also be interested in...
Biogen’s Big Day Arrives, But Aducanumab Results Don’t Answer Key Question
Biogen presented highly anticipated data in Alzheimer’s disease at CTAD for its Phase III EMERGE and ENGAGE studies, but one major question remains unanswered: will the FDA approve the drug?
Biogen’s Big Day Arrives, But Aducanumab Results Don’t Answer Key Question
Biogen presented highly anticipated data in Alzheimer’s disease at CTAD for its Phase III EMERGE and ENGAGE studies, but one major question remains unanswered: will the FDA approve the drug?
Sage Still Sees Approval Path After Depression Drug Fails In Phase III Trial
Sage Therapeutics points to patient compliance and selection as factors in its failed trial of SAGE-217. The company sees positive implications in the data as it waits for other SAGE-217 studies.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: